KNSA$40.58
Chart
Performance
Key Stats
AI KNSA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldKiniksa Pharmaceuticals presents a mixed investment profile. While its therapeutic pipeline shows promise and the company has a healthy balance sheet, its current profitability is negative, and technical indicators suggest short-term caution. The company is well-positioned in its niche, but the path to profitability needs to be closely monitored.
Thematic
Kiniksa Pharmaceuticals is focused on addressing unmet needs in cardiovascular and inflammatory diseases, areas with significant growth potential. Its product candidates target conditions with substantial patient populations and limited treatment options.
Fundamental
Kiniksa Pharmaceuticals shows a strong balance sheet with substantial cash reserves, but its current operations are not yet profitable, with negative EPS reported in several recent periods. Revenue is growing, but the company has not yet achieved consistent positive net income.
Technical
The stock is trading within its 52-week range and shows mixed signals across different timeframes. While some shorter-term indicators suggest buying pressure, longer-term moving averages indicate selling pressure, pointing to a neutral overall technical stance.
| Factor | Score |
|---|---|
| Therapeutic Focus (Cardiovascular/Inflammatory) | 85 |
| Unmet Medical Need | 90 |
| Pipeline Advancement | 80 |
| Market Size and Growth | 70 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 85 |
| Cash Flow | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Support & Resistance | 60 |
| Short-Term Oscillators | 60 |
| Volume | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Strong Cash Position
The company holds $183.581 million in cash and cash equivalents as of Q4 2024, providing ample liquidity to manage operations and pursue growth opportunities.
Positive Free Cash Flow
The company generated $25.412 million in free cash flow in the latest annual period (2024), indicating a healthy ability to cover capital expenditures and debt obligations from its core operations.
Bearish Points (8)
Negative Earnings in Recent Periods
The company reported negative EPS in Q4 2024 (-$0.18) and Q2 2024 (-$0.25), indicating profitability challenges in recent reporting periods.
Significant Net Loss
The company reported a substantial net loss of -$43.193 million in the latest annual period (2024), highlighting ongoing profitability issues.
Calendar
July 2025
29
Next Earnings Date
H: $0.37
A: $0.23
L: $0.14
H: 148.21M
A: 145.22M
L: 139.58M
Profile
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Seasonals
Price Target
38.00 USD
The 39 analysts offering 1 year price forecasts for KNSA have a max estimate of 47.00 and a min estimate of 30.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the IL-1 mediated disease space with Ilaris (canakinumab), which is approved for similar inflammatory conditions as KNSA's ARCALYST, including Cryopyrin-Associated Periodic Syndromes (CAPS) and recurrent pericarditis.
Weight: 95
Direct competitor in the IL-1 mediated disease space with Kineret (anakinra), an IL-1 receptor antagonist, approved for conditions like CAPS and Still's disease, directly competing with KNSA's therapeutic approach.
Weight: 90
A leading pharmaceutical company with a dominant and broad immunology portfolio (e.g., Humira, Skyrizi, Rinvoq). While targets may differ, they compete for market share, patient populations, and medical professionals in the broader autoimmune and inflammatory disease landscape, making them a significant competitor and potential strategic partner/acquirer.
Weight: 88
Possesses a robust and diversified immunology portfolio (e.g., Stelara, Tremfya) addressing various autoimmune and inflammatory conditions, placing them as a major competitor and influential player in the same therapeutic area as KNSA.